Payment overview · 2025
General Payments
$424.74
18 reported records · 11 companies
Healthcare provider profile · identity verified
James A. Keating, MD
Allopathic & Osteopathic Physicians|Family Medicine · HEMET, CA · NPI 1275533168
Verified facts
What the public records show
CMS Open Payments records show James A. Keating, MD received $424.74 in general payments during 2025 across 18 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Korlym.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Korlym by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.57 | 14.7% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $62.57 | 14.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.42 | 12.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.67 | 12.4% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $37.91 | 8.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.12 | 7.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.70 | 6.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.02 | 5.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.46 | 5.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.19 | 5.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.11 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.74 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $107.09 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.57 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $62.57 | 3 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.12 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 594 | 169 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 559 | 98 |
| Losartan Potassium | Losartan Potassium | 483 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 403 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 75 |
| Gabapentin | Gabapentin | 265 | 67 |
| Omeprazole | Omeprazole | 263 | 65 |
| Lisinopril | Lisinopril | 238 | 62 |
| Trazodone Hcl | Trazodone Hcl | 226 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 57 |
| Metformin Hcl | Metformin Hcl | 204 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 49 |
| Alprazolam | Alprazolam | 160 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 148 | 26 |
| Simvastatin | Simvastatin | 147 | 46 |
| Ibuprofen | Ibuprofen | 141 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 41 |
| Lorazepam | Lorazepam | 128 | 16 |
| Baclofen | Baclofen | 121 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 32 |
| Donepezil Hcl | Donepezil Hcl | 114 | 26 |
| Carvedilol | Carvedilol | 112 | 28 |
| Memantine Hcl | Memantine Hcl | 112 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 33 |
| Buspirone Hcl | Buspirone Hcl | 109 | 25 |
| Sertraline Hcl | Sertraline Hcl | 109 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 33 |
| Alendronate Sodium | Alendronate Sodium | 104 | 35 |
| Lovastatin | Lovastatin | 104 | 23 |
| Eliquis | Apixaban | 102 | 26 |
| Furosemide | Furosemide | 98 | 28 |
| Tramadol Hcl | Tramadol Hcl | 91 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 89 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 17 |
| Azithromycin | Azithromycin | 82 | 52 |
| Clonidine Hcl | Clonidine Hcl | 81 | 21 |
| Glipizide | Glipizide | 81 | 18 |
| Xarelto | Rivaroxaban | 75 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 21 |
| Meloxicam | Meloxicam | 68 | 17 |
| Atenolol | Atenolol | 67 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Allopurinol | Allopurinol | 58 | 14 |
| Potassium Chloride | Potassium Chloride | 57 | 17 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 56 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Primidone | Primidone | 52 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Temazepam | Temazepam | 51 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 50 | 12 |
| Famotidine | Famotidine | 48 | 19 |
| Methylprednisolone | Methylprednisolone | 48 | 36 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Fenofibrate | Fenofibrate | 47 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Celecoxib | Celecoxib | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 29 |
| Finasteride | Finasteride | 44 | 13 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 11 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Naproxen | Naproxen | 31 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Korlym | Mifepristone | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 13 |
| Prednisone | Prednisone | 19 | 15 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $424.74 · 18 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, ISTURISA, JARDIANCE, Kerendia, Korlym, Leqembi, RECORLEV, TRELEGY ELLIPTA, VOQUEZNA, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error